U.S. Government Assesses Drug Supply Chain Vulnerabilities

The U.S. government has initiated an assessment of vulnerabilities within the pharmaceutical supply chain.

This proactive review aims to identify critical weaknesses in drug manufacturing, distribution, and delivery that could disrupt patient access to medications.

The assessment reflects growing concern about supply chain resilience in healthcare, particularly given prior disruptions to pharmaceutical logistics and the essential nature of uninterrupted drug availability.